BioWorld

Anumana’s AI algorithm for cardiac amyloidosis gets FDA breakthrough nod

Anumana Inc. has garnered a U.S. FDA breakthrough device designation for its artificial intelligence (AI)-powered electrocardiogram-based algorithm for early identification of cardiac amyloidosis. The ...
Healio

AI algorithm for detection of cardiac amyloidosis gains FDA breakthrough device status

Please provide your email address to receive an email when new articles are posted on . An artificial intelligence-guided algorithm to identify cardiac amyloidosis received a breakthrough device ...
FOX8 Cleveland

Ultromics Announces Partnership to Expedite Development of Echo AI Algorithm for Early Detection of Cardiac Amyloidosis

OXFORD, England, Jan. 10, 2024 /PRNewswire/ -- Ultromics, a patient outcomes-focused AI-driven health technology company with roots at the University of Oxford, UK, has entered into an agreement with ...
FierceBiotech

Anumana's Pfizer-backed cardiac amyloidosis-spotting AI algorithm nabs FDA breakthrough tag

For the fourth time in half as many years, Anumana has earned the FDA’s breakthrough device designation for another of its artificial intelligence algorithms designed to catch hard-to-spot heart ...